Stockscreener 앱 받기
7.35
1.08%
-0.08
시간 외 거래:
7.37
0.02
+0.27%
전일 마감가:
$7.43
열려 있는:
$7.5
하루 거래량:
57,671
Relative Volume:
0.84
시가총액:
$220.71M
수익:
$8.98M
순이익/손실:
$-31.39M
주가수익비율:
-5.4851
EPS:
-1.34
순현금흐름:
$-24.83M
1주 성능:
-2.91%
1개월 성능:
+1.52%
6개월 성능:
-24.54%
1년 성능:
-5.65%
1일 변동 폭
$7.22
$7.55
1주일 범위
$7.07
$7.60
52주 변동 폭
$6.78
$11.42
프로파운드 메디컬 Stock (PROF) Company Profile
PROF을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PROF
Profound Medical Corp
|
7.35 | 220.71M | 8.98M | -31.39M | -24.83M | -1.34 |
|
ABT
Abbott Laboratories
|
113.48 | 196.83B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
383.42 | 146.17B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
98.66 | 145.41B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.08 | 112.94B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
69.78 | 41.16B | 6.60B | 4.16B | 490.10M | 6.93 |
프로파운드 메디컬 Stock (PROF) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-23 | 개시 | Lake Street | Buy |
| 2024-07-16 | 업그레이드 | Stifel | Hold → Buy |
| 2023-11-28 | 개시 | Stifel | Hold |
| 2023-08-04 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-03-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-09-15 | 개시 | Jefferies | Buy |
모두보기
프로파운드 메디컬 주식(PROF)의 최신 뉴스
Profound Medical Corp.'s (TSE:PRN) Profit Outlook - Yahoo Finance
Profound Medical Adjusts J.P. Morgan Conference Schedule for Enhanced Visibility - TipRanks
Update: Profound Medical's Scheduled Presentation at the 43rd Annual J.P. Morgan Healthcare Conference Moved Up to 9:00am PT on January 16th - The Manila Times
Profound Medical Corp. Issues Preliminary Unaudited Revenues Report for Q4 2024 - Defense World
Stocks In Play - Baystreet.ca
Does Profound Medical (PROF) Have the Potential to Rally 100.13% as Wall Street Analysts Expect? - MSN
Stocks In Play: Profound Medical Corp. By Baystreet.ca - Investing.com Canada
Profound Medical Corp (PRN-T) QuotePress Release - The Globe and Mail
Profound Medical Corp. - Baystreet.ca
Profound Medical Corp. Provides Earnings Guidance for the Fourth Quarter and for Full Year of 2024 - Marketscreener.com
Profound Medical reports FY24 revenue above consensus - MSN
Profound Medical Reports Robust Revenue Growth and Transition to U.S. GAAP - TipRanks
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues - The Manila Times
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues - Benzinga
Profound Medical (TSE:PRN) Stock Price Down 2.2%Time to Sell? - MarketBeat
Profound Medical (TSE:PRN) Shares Down 2.2% – Here’s What Happened - Defense World
Profound Medical to Present at J.P. Morgan Healthcare Conference - TipRanks
Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Key factors to consider when considering risk and progression of BPH - Urology Times
Profound Medical (TSE:PRN) soars 14% this week, taking one-year gains to 18% - Simply Wall St
Profound Medical stock reaffirmed at Buy at Lake Street on favourable setup in 2025 - Investing.com Canada
Profound Medical Corp (PRN-T) Profile - The Globe and Mail
Profound Medical stock hits 52-week low at $6.87 amid market challenges - Investing.com
Critical Survey: enVVeno Medical (NASDAQ:NVNO) versus Profound Medical (NASDAQ:PROF) - Defense World
Profound Medical (NASDAQ:PROF) versus Westaim (OTCMKTS:WEDXF) Critical Contrast - Defense World
Closing Bell: Profound Medical Corp Down On Thursday (PRN) - Barchart
Profound Medical Successfully Prices Public Offering to Boost Commercialization Efforts - TipRanks
Raymond James Boosts Earnings Estimates for Profound Medical - MarketBeat
Raymond James Has Positive Outlook for PROF FY2024 Earnings - MarketBeat
FY2024 EPS Estimate for Profound Medical Lifted by Analyst - Defense World
FY2024 EPS Forecast for Profound Medical Boosted by Analyst - Defense World
Profound Medical stock hits 52-week low at $7.01 amid market shifts - Investing.com Australia
Profound Medical stock hits 52-week low at $7.01 amid market shifts By Investing.com - Investing.com South Africa
Tumor Ablation Market Share, Opportunities Analysis, Recent Trends, Regional Growth And Outlook By 2033 - WhaTech
Chairman of the Board & CEO of Profound Medical Picks Up 3.7% More Stock - Yahoo Finance UK
Profound Medical keeps “Strong Buy” rating at Raymond James - Cantech Letter
Wellington Weekly - substack.com
Profound Medical closes UPO of common shares - Medical Buyer
Profound Medical Raises $40.25 Million in Public Offering - TipRanks
Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares - Financial Post
Profound Medical’s CEO discusses the potential of TULSA-PRO for prostate disease treatment - Fierce Biotech
Profound Medical announces pricing of $35 mln public offering - TradingPedia
Gleamer raises €4.5M for radiology AI - Medical Buyer
Profound Medical’s $35M Public Offering Announcement - TipRanks
Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares - The Manila Times
Profound Medical partners with Siemens for MR-guided prostate therapy solution - DOTmed
Presidio Medical™ appoints Richard J. Buchholz to its Board - Medical Buyer
Profound Medical Corp to sell common shares - Medical Buyer
GIC to raise its stake in Asia Healthcare Holdings - Medical Buyer
Profound Medical announces proposed public offering; shares fall - MSN
Profound Medical Plans Public Share Offering - TipRanks
프로파운드 메디컬 (PROF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.25%
0.57%
자본화:
|
볼륨(24시간):